Left ventricular assist device thrombosis: Another piece of the puzzle?

JACC: Heart Failure

Volumn 3, Issue 2, 2015, Pages 154-158

  Lindenfeld, JoAnn ^a   Keebler, Mary E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erythropoiesis stimulating agents; LVAD; Thrombosis

Indexed keywords

ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN; HEMOGLOBIN; HLA ANTIGEN; LACTATE DEHYDROGENASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTERIOVENOUS FISTULA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG SAFETY; EDITORIAL; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; IRON DEFICIENCY; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR ASSIST DEVICE THROMBOSIS; MALIGNANT HYPERTENSION; MEDICAL DEVICE COMPLICATION; NONHUMAN; OXIDATIVE STRESS; PRACTICE GUIDELINE; PULSATILE FLOW; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; FEMALE; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; MALE; MORTALITY;

FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HEMATINICS; HUMANS; MALE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84922025247     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.12.001     Document Type: Editorial

References (37)

1. Frazier O.H., Rose E.A., Oz M.C., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. JThorac Cardiovasc Surg 2001, 122:1186-1195. HeartMate LVAS Investigators. Left ventricular assist system.
2. Slaughter M.S., Rogers J.G., Milano C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. NEngl J Med 2009, 361:2241-2251. HeartMate II Investigators.
3. Starling R.C., Moazami N., Silvestry S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. NEngl J Med 2014, 370:33-40.
4. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. JHeart Lung Transplant 2014, 33:12-22.
5. Cowger J.A., Romano M.A., Shah P., et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. JHeart Lung Transplant 2014, 33:35-43.
6. Ravichandran A.K., Parker J., Novak E., et al. Hemolysis in left ventricular assist device: a retrospective analysis of outcomes. JHeart Lung Transplant 2014, 33:44-50.
7. Uriel N., Han J., Morrison K.A., et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. JHeart Lung Transplant 2014, 33:51-59.
8. Mehra M.R., Stewart G.C., Uber P.A. The vexing problem of thrombosis in long-term mechanical circulatory support. JHeart Lung Transplant 2014, 33:1-11.
9. McIlvennan C.K., Page R.L., Ambardekar A.V., Brieke A., Lindenfeld J. Activated partial thromboplastin time overestimates anti-coagulation in left ventricular assist device patients. JHeart and Lung Transplant 2014, 33:1312-1314.
10. Glaspy J.A. Erythropoietin in cancer patients. Annu Rev Med 2009, 60:181-192.
11. Nassif M.E., Patel J.S., Shuster J.E., et al. Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JAm Coll Cardiol HF 2015, 3:146-153.
12. Vrtovec B., Radovancevic R., Delgado R.M., et al. Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circulatory support. Eur J Heart Fail 2009, 11:1000-1004.
13. Weltert L., D'Alessandro S., Nardella S., et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: arandomized blind controlled study. JThorac Cardiovasc Surg 2010, 139:621-626.
14. Velez M., Johnson M.R. Management of allosensitized cardiac transplant candidates. Transplant Rev 2009, 23:235-247.
15. Winearls C.G., Oliver D.O., Pippard M.J., et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986, 22:1175-1178.
16. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989, 111:992-1000.
17. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. NEngl J Med 1998, 339:584-590.
18. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. NEngl J Med 2006, 355:2085-2098.
19. Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. NEngl J Med 2006, 355:2071-2084. CREATE Investigators.
20. Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388.
21. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. Atrial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEngl J Med 2009, 361:2019-2032.
22. U.S. Food and Drug Administration. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Available at: Accessed October 26,2014. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126481.htm.
23. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Supp 2012, 2:279-335.
24. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526-535. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
25. Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. NEngl J Med 2013, 368:1210-1219. RED-HF Committees, RED-HF Investigators.
26. Qaseem A., Humphrey L.L., Fitterman N., et al. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2013, 159:770-779.
27. Koulouridis I., Alfayez M., Trikalinos T.A., et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013, 61:44-56.
28. Vaziri N.D., Zhou X.J. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009, 24:1082-1088.
29. Kadikoylu G., Yavasoglu I., Bolaman Z., et al. Platelet parameters in women with iron deficiency anemia. JNatl Med Assoc 2006, 98:398-402.
30. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. AmJ Kidney Dis 2008, 52:727-736.
31. Park M.J., Park P.W., Seo Y.H., et al. The relationship between iron parameters and platelet parameters in women with iron deficiency anemia and thrombocytosis. Platelets 2013, 24:348-351.
32. Anker S.D., Comin Colet J., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. NEngl J Med 2009, 361:2436-2448. FAIR-HF Trial Investigators.
33. Beguin Y., Loo M., R'Zik S., et al. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 1994, 53:265-270.
34. Stohlawetz P.J., Dzirlo L., Hergovich N., et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000, 95:2983-2989.
35. Homoncik M., Jilma-Stohlawetz P., Schmid M., et al. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004, 20:437-443.
36. Turner S.J., Ketch T.R., Gandhi S.K., Sane D.C. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 2008, 155:806-816.
37. Santayana G. Reason in Common Sense: Volume One: The Life of Reason 1980, Dover Publications, New York.